Trial Profile
A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline And Who Are Taxane Resistant Who Have Completed Study CA163107 And Who Are Benefiting From Continuation On Therapy With Ixabepilone
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Feb 2017
Price :
$35
*
At a glance
- Drugs Ixabepilone (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb